What's Happening?
The USC Epstein Family Alzheimer’s Therapeutic Research Institute (ATRI), located in Sorrento Valley, is initiating two significant clinical trials focused on Alzheimer's disease (AD) in individuals with Down syndrome. Dr. Michael Rafii, medical director
of ATRI, highlighted that approximately 95% of people with Down syndrome develop AD by age 40, making it the leading cause of death for this population. The first trial, ALADDIN, will evaluate donanemab, an FDA-approved therapy known to remove beta-amyloid plaques, to determine its efficacy in people with Down syndrome. The second trial, APPlauDS, will take a more targeted approach by focusing on the APP gene on chromosome 21, which is responsible for the overproduction of beta-amyloid in individuals with Down syndrome. This genetic predisposition, where people with Down syndrome have three copies of chromosome 21 instead of two, leads to earlier onset of AD, typically in their early 40s, with dementia developing around age 53. These trials aim to translate 15 years of research into effective treatments for this specific population.
Why It's Important?
These clinical trials are crucial because individuals with Down syndrome have historically been excluded from many Alzheimer's treatment trials, despite being the largest population genetically predisposed to the disease. The ALADDIN trial's investigation of donanemab could expand the application of an already FDA-approved therapy to a vulnerable group, potentially offering a new treatment pathway. The APPlauDS trial's focus on the APP gene represents a highly targeted approach, aiming to address the root genetic cause of amyloid overproduction in Down syndrome-related AD. Success in these trials could significantly alter the prognosis for people with Down syndrome, delaying or preventing the onset of dementia and improving their quality of life. Furthermore, the research highlights the importance of inclusive clinical trials and the need to address health disparities in specific populations, ensuring that advancements in AD treatment benefit all who are affected.
What's Next?
The ALADDIN and APPlauDS trials are currently underway, with their progress and results anticipated to provide critical data on the effectiveness of these targeted therapies for Down syndrome-related Alzheimer's disease. The findings from these trials will inform future treatment strategies and potentially lead to new FDA approvals or expanded indications for existing drugs. Beyond the immediate trial outcomes, ATRI plans to continue its efforts in Alzheimer's disease prevention, research, and care for people with Down syndrome. The institute is also working to raise awareness and encourage action to ensure that therapies are accessible to this population. The ongoing research at ATRI, supported by grants like that from the Linda and Mike Mussallem Foundation, aims to develop treatments that can delay, prevent, or effectively treat AD, ultimately enabling people with Down syndrome to live longer, healthier lives free from dementia.
Beyond the Headlines
The research by ATRI delves into the ethical and societal implications of medical research, particularly the historical exclusion of certain populations from clinical trials. By actively including individuals with Down syndrome, these trials challenge existing norms and advocate for more equitable access to advanced medical treatments. The focus on the genetic underpinnings of Down syndrome-related Alzheimer's disease also offers broader insights into the mechanisms of AD, which could have implications for understanding and treating other forms of the disease. The initiative also underscores the importance of community support and specialized care facilities, such as Noah Homes, which provide dedicated memory care for adults with developmental disabilities. This integrated approach, combining cutting-edge research with practical care solutions, reflects a growing recognition of the complex needs of this population and the necessity of a holistic strategy to combat Alzheimer's disease.
